Telomir Pharmaceuticals (TELO) Liabilities and Shareholders Equity (2022 - 2026)

Telomir Pharmaceuticals has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $7.3 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 454.48% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.1 million (up 101.54% YoY) and the FY2025 annual result came in at $7.3 million, up 454.48% from the prior year.
• Liabilities and Shareholders Equity fell to $7.3 million in Q4 2025 per TELO's latest filing, from $7.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $7.4 million in Q3 2025 and troughed at $48730.0 in Q4 2022.
• A 4-year average of $2.9 million and a median of $1.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity soared 9696.36% in 2023, then sank 85.98% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $48730.0 in 2022, then jumped by 9696.36% to $4.8 million in 2023, then sank by 72.26% to $1.3 million in 2024, then jumped by 454.48% to $7.3 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $7.3 million, $7.4 million, and $829611.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.